Clinical trialPhase 3Unknown
Hyperthermia European Adjuvant Trial
A Randomized Two-armed Open Study on the Adjuvant Therapy in Patients With R0/R1 Resected Pancreatic Carcinoma With Gemcitabine Plus Capecitabine (Arm GC) vs. Gemcitabine Plus Cisplatin With Regional Hyperthermia (Arm GPH)
- Outcome
- Outcome unknown
- Phase
- Phase 3
- Status
- Unknown
- Study type
- Interventional
- Start
- March 2012
- Expected end
- March 2021
- Enrollment
- 336 participants
- Sites
- 1
- Primary outcomes
- Disease-free survival (DFS)
- Sponsor
- Other
- Results posted
- No
- Last update
- 17 November 2017
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Improvement of the clinical outcome in patients with resectable pancreatic carcinoma through an intensified adjuvant treatment with gemcitabine, cisplatin and regional deep hyperthermia as compared to standard chemotherapy.
Papers 1
- Registry-listed results paperRegional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ducta… DOI 10.1016/j.ejca.2022.12.009↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.